Health organizations in Europe denounced a clear correlation between people who were vaccinated with the AstraZeneca vaccine and then suffered rare blood clots that, in many cases, ended in the death of the patient. 

Marco Cavaleri, chairman of the EMA’s vaccine evaluation team, confirmed to the newspaper Il Messaggero when asked about the possible link between the AstraZeneca injection and the cases of blood clots in the brain, that: “In my opinion, we can now say it, it is clear that there is an association with the vaccine. However, we still don’t know what causes this reaction,” Reuters reported.

The vaccine expert explained that among those vaccinated with AstraZeneca, there is “a higher than expected number of cases of cerebral thrombosis with platelet deficiency among young people.” He also points out that young women are “protagonists of thrombosis cases.”

Also, Cavaleri implied that the EMA in the coming hours would admit that the “connection is there,” but it is still necessary to understand “how it happens” and “what causes that reaction.”

Lee Merritt, M.D., looked into reports in the Vaccine Adverse Event Reporting System (VAERS) of reactions to Pfizer and Moderna products that could have been related to platelet problems after the post-vaccination death of a 56-year-old Florida physician from a brain hemorrhage, and reports of clotting problems worldwide after the Astra-Zeneca jab.

Her article in the Journal of American Physicians and Surgeons’ summer issue outlines the different ways these problems can manifest.

Following injection with mRNA technology COVID vaccines, thrombocytopenia has been documented. The VAERS (Vaccine Adverse Event Reporting System) database was searched for cases of overt thrombocytopenia and bleeding issues, as these could be symptoms of the same condition.

358 records were gathered and examined using search phrases designed to discover similar cases and entered between December 15, 2020, and March 12, 2021. There were 104 cases of thrombocytopenia, 90 of which were severe. The majority of cases in the severe group had platelet counts below 3000 when reported. Even minor bleeding issues, such as nasal bleeds, presented in an unexpected way.

Using the search keywords: platelets, bleeding, hemorrhage, ITP, thrombocytopenia, thrombocytopenia, bleed, hemorrhagic, spotting, epistaxis, hematuria, stroke, bruise, purpura, hemoptysis, hematuria, pancytopenia, and haematologic. The field was further reduced to search exclusively for Pfizer and Moderna manufacturers in order to confine the study to goods utilizing mRNA technology in general use in the United States from December 15, 2020, to March 12, 2021.

370 results were found. Five instances were eliminated because there was insufficient information to adequately characterize the problem, and seven others were eliminated because the patients did not fit the inclusion criteria for hematological disease or hemorrhage.

 By May, searching the VAERS database, using the identical 19 keywords for the same date range, 6290 entries were retrieved, including 291 deaths. Numbers were increasing daily, reflecting the backlog in data entry.

Table 1 contains the 358 entries from December 15, 2020, to March 12, 2021.

Lee Merritt’s article: Journal of American Physicians and Surgeons

There were 105 cases of thrombocytopenia, with 94 cases of severe thrombocytopenia, 11 cases of mild thrombocytopenia, and five cases with petechial rash/bruising but no platelet counts. Two cases of pancytopenia, a case of Burkitt’s lymphoma, and a case of myeloid leukemia, all diagnosed at the time of the report, were placed in the severe group because they had low platelets in the context of other larger hematologic illnesses.

Four young people aged 18 to 29 were diagnosed with thrombocytopenia: one male and one female in the severe group, and two women in the group merely reporting a petechial rash or multifocal bruises. There were 49 female patients and 55 male patients in the cases where the gender was known.

Table 2 shows the ages of patients with severe thrombocytopenia.

Lee Merritt’s article: Journal of American Physicians and Surgeons

“VAERS has the potential to shorten recognition time by trying to spot ‘unusual patterns,’” Dr. Merritt writes. “But this requires that physicians be aware of the system and take the time to enter any suspected side effect—not just the worst cases.” a report presented to the Agency for Healthcare Research and Quality showed less than 1% of adverse events are reported to VAERS.

“It is incumbent upon physicians who recommend these experimental agents to follow their patients, become familiar with VAERS…, and employ the precautionary principle,” Dr. Merritt concludes.